Glaukos Corp GKOS
We take great care to ensure that the data presented and summarized in this overview for GLAUKOS Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding GKOS
View all-
Black Rock Inc. New York, NY7.9MShares$871 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.31MShares$586 Million0.01% of portfolio
-
Brown Capital Management LLC Baltimore, MD2.13MShares$235 Million3.61% of portfolio
-
State Street Corp Boston, MA1.83MShares$201 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X01.61MShares$178 Million0.09% of portfolio
-
Invesco Ltd. Atlanta, GA1.6MShares$177 Million0.03% of portfolio
-
Lord, Abbett & Co. LLC Jersey City, NJ1.51MShares$167 Million0.47% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN1.46MShares$161 Million0.04% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.33MShares$146 Million0.06% of portfolio
-
Fred Alger Management, LLC New York, NY1.23MShares$136 Million0.59% of portfolio
Latest Institutional Activity in GKOS
Top Purchases
Top Sells
About GKOS
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
Insider Transactions at GKOS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 15
2024
|
Marc Stapley |
SELL
Open market or private sale
|
Direct |
6,250
-5.72%
|
$700,000
$112.8 P/Share
|
|
May 15
2024
|
Marc Stapley |
BUY
Exercise of conversion of derivative security
|
Direct |
6,250
+13.93%
|
$200,000
$32.0 P/Share
|
|
May 10
2024
|
Alex R. Thurman SVP & CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
353
-0.34%
|
$38,830
$110.83 P/Share
|
|
May 10
2024
|
Joseph E Gilliam PRESIDENT & COO |
SELL
Open market or private sale
|
Direct |
2,395
-2.3%
|
$263,450
$110.56 P/Share
|
|
May 10
2024
|
Joseph E Gilliam PRESIDENT & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,395
+2.25%
|
$131,725
$55.18 P/Share
|
|
May 06
2024
|
Joseph E Gilliam PRESIDENT & COO |
SELL
Open market or private sale
|
Direct |
105
-0.1%
|
$11,550
$110.36 P/Share
|
|
May 06
2024
|
Joseph E Gilliam PRESIDENT & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
105
+0.1%
|
$5,775
$55.18 P/Share
|
|
May 06
2024
|
Alex R. Thurman SVP & CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
90
-0.17%
|
$9,900
$110.26 P/Share
|
|
May 02
2024
|
Alex R. Thurman SVP & CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
442
-0.28%
|
$46,852
$106.53 P/Share
|
|
May 02
2024
|
Joseph E Gilliam PRESIDENT & COO |
SELL
Open market or private sale
|
Direct |
2,059
-0.5%
|
$216,195
$105.93 P/Share
|
|
May 02
2024
|
Joseph E Gilliam PRESIDENT & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,059
+1.94%
|
$142,071
$69.3 P/Share
|
|
Apr 10
2024
|
David F Hoffmeister |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+38.81%
|
$70,000
$7.28 P/Share
|
|
Apr 08
2024
|
Joseph E Gilliam PRESIDENT & COO |
SELL
Open market or private sale
|
Direct |
59,801
-10.29%
|
$5,980,100
$100.89 P/Share
|
|
Apr 08
2024
|
Joseph E Gilliam PRESIDENT & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
59,801
+27.0%
|
$2,451,841
$41.69 P/Share
|
|
Apr 08
2024
|
Alex R. Thurman SVP & CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,372
-1.28%
|
$137,200
$100.85 P/Share
|
|
Apr 05
2024
|
Alex R. Thurman SVP & CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
262
-0.16%
|
$25,152
$96.52 P/Share
|
|
Apr 05
2024
|
Joseph E Gilliam PRESIDENT & COO |
SELL
Open market or private sale
|
Direct |
2,457
-2.36%
|
$235,872
$96.81 P/Share
|
|
Apr 05
2024
|
Joseph E Gilliam PRESIDENT & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,457
+2.3%
|
$135,135
$55.18 P/Share
|
|
Apr 04
2024
|
Joseph E Gilliam PRESIDENT & COO |
SELL
Open market or private sale
|
Direct |
200
-0.2%
|
$19,200
$96.57 P/Share
|
|
Apr 04
2024
|
Joseph E Gilliam PRESIDENT & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
200
+0.2%
|
$11,000
$55.18 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 107K shares |
|---|---|
| Exercise of conversion of derivative security | 842K shares |
| Bona fide gift | 28.5K shares |
| Open market or private sale | 871K shares |
|---|---|
| Payment of exercise price or tax liability | 41.9K shares |
| Bona fide gift | 28.5K shares |